Kratom and drug testing: what tests detect, and how testing works in Canada

“Does kratom show up on a drug test?” is one of the most-searched kratom questions in Canada, and most answers online come from vendors. This guide summarizes what the toxicology literature and testing-industry sources say: which tests can detect kratom alkaloids, which cannot, how long detection has been reported to last, and how Canadian workplace testing is structured. It is information about how testing works. It is not advice on passing or avoiding a test, and it does not tell you whether to use kratom.

Last reviewed: November 9, 2026. Part of the KratomSource knowledge base.

Standard panels do not look for it

The urine screens most often used for employment, the 5-panel and 10-panel immunoassays and their oral-fluid equivalents, test for defined drug classes: cannabinoids, cocaine metabolite, amphetamines, opiates and opioids, phencyclidine, and in wider panels benzodiazepines, barbiturates, methadone and others. Mitragynine is structurally unrelated to morphine and is not a target of the opiate immunoassay. On a standard panel, kratom alkaloids are generally not detected.

Tests that do detect it

Laboratories can and do test for mitragynine and 7-hydroxymitragynine specifically, using liquid chromatography with tandem mass spectrometry (LC-MS/MS) or a dedicated immunoassay. Kratom-specific tests are offered by major reference labs and appear in some expanded panels used in addiction medicine, pain-management monitoring, probation and court programmes, child-protection cases, some military and safety-sensitive settings, and post-mortem toxicology. Whether a given test includes kratom depends entirely on what the requesting organization ordered.

Reported detection windows

The best pharmacokinetic data come from a study of ten long-term users in Thailand (Trakulsrichai and colleagues, 2015), which reported a terminal half-life for mitragynine of roughly a day, with wide variation between individuals. On that basis, and from laboratory experience, urine detection is usually described as lasting several days after last use and longer in heavy daily users; blood and oral-fluid windows are shorter, and hair testing, where offered, can reflect months. These are population descriptions with large individual variation, drawn from small studies. Nobody can responsibly give a precise figure for an individual.

False positives and cross-reactions

Case reports and laboratory notes describe occasional unexpected results on immunoassay screens in people using kratom, including reported screening positives for methadone on some assays that did not confirm on mass spectrometry. A separate and more serious problem is contamination: products sold as kratom in North America have been found to contain other drugs, including synthetic opioids, which will produce a true positive for that drug. This is one more reason a product with no lot-specific adulterant screen is an unknown quantity; see lab testing explained.

How workplace testing works in Canada

• No general right to test. Canadian human-rights and arbitration law limits workplace drug testing mostly to safety-sensitive positions, and usually to reasonable-cause, post-incident and return-to-work situations. Random testing is permitted only in narrow circumstances.
• Cross-border transport follows US rules. Canadian truck and bus drivers who operate into the United States are tested under US Department of Transportation rules, which specify a fixed panel (marijuana, cocaine, amphetamines, opioids, PCP). Kratom is not on it.
• Employers can specify more. Outside regulated panels an employer’s policy can list additional substances, and impairment at work is a policy matter whether or not a substance is on a panel.
• Legal status is not the test. Kratom is not a controlled substance in Canada, but a workplace policy can prohibit impairment from any substance, legal or not. Alcohol is the obvious parallel.

Medical settings

Clinicians ordering toxicology in an emergency, before surgery or during pregnancy may not get a kratom result from a routine screen. The published interaction and adverse-event reports in our research summary are the reason medical sources ask patients to disclose kratom use rather than rely on a screen to find it.

Sources

• Trakulsrichai S et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther 2015;9:2421–2429.
• Le D, Goggin MM, Janis GC. Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom. J Anal Toxicol 2012;36:616–625.
• US Department of Transportation, 49 CFR Part 40, drug testing panel for safety-sensitive transportation employees.
• Supreme Court of Canada, Communications, Energy and Paperworkers Union of Canada, Local 30 v. Irving Pulp & Paper, Ltd., 2013 SCC 34 (limits on random workplace testing).
• Canadian Human Rights Commission, Impaired at Work: A guide to accommodating substance dependence.
• Kruegel AC, Grundmann O. Neuropharmacology 2018;134:108–120 (metabolism of mitragynine).

Frequently asked questions

Does kratom show up on a standard drug test?

Generally no. Standard 5- and 10-panel immunoassay screens do not target mitragynine, which is structurally unrelated to morphine.

Can a lab test for kratom specifically?

Yes. Reference labs offer mitragynine and 7-hydroxymitragynine testing by LC-MS/MS or dedicated immunoassay, used in some clinical, legal and safety-sensitive settings.

How long is kratom detectable?

Small studies report a mitragynine half-life of roughly a day with wide individual variation; urine detection is usually described as several days, longer with heavy daily use. No precise figure applies to an individual.

Is kratom on the DOT panel used for Canadian cross-border truckers?

No. The US Department of Transportation panel covers marijuana, cocaine, amphetamines, opioids and PCP.